# Cognitive and Psychophysiological Effects of Delta-9-Tetrahydrocannabinol in Bipolar Disorder

> **NCT03206463** · PHASE1 · TERMINATED · sponsor: **Yale University** · enrollment: 2 (actual)

## Conditions studied

- Delta-9-Tetrahydroncannabinol
- Bipolar Disorder
- Healthy Controls

## Interventions

- **DRUG:** 4 mg Delta-9-THC
- **DRUG:** Placebo
- **DRUG:** 2 mg Delta-9-THC

## Key facts

- **NCT ID:** NCT03206463
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-08-01
- **Primary completion:** 2017-09-29
- **Final completion:** 2017-09-29
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Feasibility pilot was completed
- **Last updated:** 2022-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03206463

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03206463, "Cognitive and Psychophysiological Effects of Delta-9-Tetrahydrocannabinol in Bipolar Disorder". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03206463. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*